Intelligent Bio Solutions Raises $10 Million in AT Market Placement with $4.10 Strike Warrants
Intelligent Bio Solutions closed an at-the-market private placement of 2.3 million shares and matching Series K-1 and K-2 warrants at $4.35 each, raising about $10.0 million in gross proceeds. Proceeds will fund working capital, a 510(k) FDA submission for its Intelligent Fingerprinting drug screening system and accelerate international expansion.
1. Successful $10 Million Capital Raise Bolsters Liquidity
Intelligent Bio Solutions Inc. closed a private placement with two healthcare-focused institutional investors, securing gross proceeds of approximately $10.0 million by issuing 2,298,850 shares of common stock at $4.35 per share along with equal tranches of Series K-1 and K-2 warrants. Each warrant entitles holders to purchase one additional share at $4.10 per share and carries a five-year term following SEC effectiveness of the associated registration statement. Placement agent fees and offering expenses remain to be deducted, but the transaction strengthens INBS’s balance sheet and extends its operational runway into 2027.
2. Proceeds Target FDA Submission and International Rollout
Management intends to deploy the new funds toward working capital, completion of a 510(k) submission for its Intelligent Fingerprinting Drug Screening System, and expansion into Europe and Asia. The non-invasive fingerprint sweat analyzer, which delivers results in under ten minutes, targets workplace testing in safety-critical industries such as transport, mining and manufacturing. With prior pilots demonstrating over 95% concordance against traditional urine assays, the company expects regulatory clearance by the end of the second quarter and initial revenue contributions from overseas distributors by midyear.
3. New Manufacturing Partnership Drives Cost Reduction and Scalability
INBS announced a strategic alliance with a California-based medical device contract manufacturer to streamline production of its disposable test cartridges. The agreement targets a 30% reduction in per-unit manufacturing costs through economies of scale and automated assembly lines. The partnership also secures priority capacity to support a planned tenfold increase in monthly output ahead of U.S. commercial launch, positioning the company to meet growing demand from occupational health providers.
4. Stock Reacts with Over 130% Rally on Strategic Announcements
Following disclosure of the financing and manufacturing deal, INBS shares surged more than 132% in a single trading session, reflecting investor confidence in the company’s strengthened capital structure and accelerated path to revenue. Trading volume spiked to ten times its three-month daily average, underscoring broad market interest. Analysts have revised their operational outlooks, forecasting break-even cash flow by the fourth quarter and projecting annual revenues of $25 million by year-end 2027.